

AroCell patent approved by the Chinese patent office

AroCell AB (publ) announced today that the patent no 105980407 and titled "Monoclonal anti-TK1 antibodies" is granted by China National Intellectual Property Administration (CNIPA).

The patent relates to AroCell's proprietary monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. The antibodies approved in the patent is used in the AroCell TK 210 ELISA kit.

"We are delighted that this patent has been granted by China National Intellectual Property Administration. This reinforces our patent position in China and increases AroCell's attractiveness as a business partner in Asia. We will continue to develop our portfolio of proprietary assets to further expand our business opportunities and to support our product AroCell TK 210 ELISA." says Michael Brobjer, CEO AroCell.

Contacts

Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-02-11 12:45 CET.

Attachments

[AroCell patent approved by the Chinese patent office](#)